Fig. 2.

Percent change from baseline in TTR tetramer fold stabilization relative to tafamidis:TTR molar ratio in the plasma of healthy volunteers. The data presented originate from two Phase 1, randomized, double-blind, ascending dose tolerance studies. In study Fx-002, healthy adults aged 18–65 years with a body mass index of 19–29 kg/m² administered single doses of up to 120 mg tafamidis. In study B3461040 (ClinicalTrials.gov identifier, NCT01655511), healthy adults aged 21–55 years with a body mass index of 17.5–30.5 kg/m² administered single doses of up to 480 mg tafamidis. TTR transthyretin